Skip to main content
  • Clinical
      |Clinical
    • Acute Coronary Syndromes
    • Cardiac Surgery
    • Covid-19
    • Heart Failure
    • Heart Health
    • Heart Rhythm
    • Hypertension
    • Interventional Cardiology
    • Mitral Valve
    • Pharmaceutics
    • Structural Heart Disease
    • TAVR
    • Tricuspid Valve
    • Vascular & Endovascular
  • Management
      |Management
    • Chest Pain Guidelines
    • Compensation
    • Economics
    • Education & Training
    • Legal News
    • Patient Care
    • Policy & Regulations
    • Professional Associations
    • Quality
    • Revenue
    • Staffing
  • Technology
      |Technology
    • AI
    • Cardiac Imaging
    • Cath Lab
    • CT
    • CVIS
    • ECG
    • Echo
    • EP Lab
    • Informatics
    • MRI
    • Nuclear Cardiology
    • Remote Monitoring
  • Videos
  • Conferences
      |Conferences
    • ACC
    • AHA
    • ASE
    • ASNC
    • ESC
    • EuroPCR
    • HFSA
    • HRS
    • HRS
    • SCAI
    • SCCT
    • SIIM
    • SNMMI
    • STS
    • TCT
    • VIVA
  • Custom Content
      |Custom Content
    • Experience Stories
    • Webinars & Videos
  • Subscribe
  • Forty Under 40 Award
      |Forty Under 40 Award
    • Class of 2026
    • Class of 2025

Search form

Home

News You Need to Know Today
Pfizer gains cardiovascular treatments in new $6.7B deal | Telehealth appointments for heart failure provide value
Tuesday, March 15, 2022
Link to Twitter Link to Facebook Link to Linkedin Link to Vimeo

Today's News and Trends

Pfizer finalizes $6.7 billion acquisition of Arena Pharmaceuticals, gaining key cardiovascular treatments

Etrasimod, an oral medication developed to treat certain inflammatory conditions, was at the center of Pfizer’s acquisition, but some key cardiovascular assets were also part of the transaction. 

READ MORE >
Share on Twitter Share on Facebook Share on Linkedin

Pfizer finalizes $6.7 billion acquisition of Arena Pharmaceuticals, gaining key cardiovascular treatments

Share on Twitter Share on Facebook Share on Linkedin
Etrasimod, an oral medication developed to treat certain inflammatory conditions, was at the center of Pfizer’s acquisition, but some key cardiovascular assets were also part of the transaction. 
READ MORE >

Telehealth provided value for heart failure patients during COVID-19 pandemic

Overall, researchers found, 30-day readmission was less common when heart failure patients used telehealth to check in with a physician after discharge. 

READ MORE >
A patient has a telehealth visit with their doctor remotely in their home via video conferencing. The COVID-19 cause massive movement to telehealth since 2020.
Share on Twitter Share on Facebook Share on Linkedin

Telehealth provided value for heart failure patients during COVID-19 pandemic

Share on Twitter Share on Facebook Share on Linkedin
A patient has a telehealth visit with their doctor remotely in their home via video conferencing. The COVID-19 cause massive movement to telehealth since 2020.
Overall, researchers found, 30-day readmission was less common when heart failure patients used telehealth to check in with a physician after discharge. 
READ MORE >

Featured Articles

AI-powered ECG analysis could boost care for patients with hypertrophic cardiomyopathy

Advanced algorithms can pick up on key details in a 12-lead ECG that human readers are unable to see. 

READ MORE >
Share on Twitter Share on Facebook Share on Linkedin

AI-powered ECG analysis could boost care for patients with hypertrophic cardiomyopathy

Share on Twitter Share on Facebook Share on Linkedin
Advanced algorithms can pick up on key details in a 12-lead ECG that human readers are unable to see. 
READ MORE >

AFib, AI and heart-healthy diets: European Society of Cardiology previews EHRA 2022

The European Heart Rhythm Association's annual conference is headed to Denmark. 

READ MORE >
EHRA 2022, the yearly get-together hosted by the European Heart Rhythm Association (EHRA), is scheduled for April 3-5 at the Bella Center in Copenhagen, Denmark. European Society of Cardiology
Share on Twitter Share on Facebook Share on Linkedin

AFib, AI and heart-healthy diets: European Society of Cardiology previews EHRA 2022

Share on Twitter Share on Facebook Share on Linkedin
EHRA 2022, the yearly get-together hosted by the European Heart Rhythm Association (EHRA), is scheduled for April 3-5 at the Bella Center in Copenhagen, Denmark. European Society of Cardiology
The European Heart Rhythm Association's annual conference is headed to Denmark. 
READ MORE >

In Case You Missed It

Pig heart transplant patient dies 2 months after historic procedure

The 57-year-old patient was able to communicate with his family in his final hours. 

READ MORE >
David Bennett
Share on Twitter Share on Facebook Share on Linkedin

Pig heart transplant patient dies 2 months after historic procedure

Share on Twitter Share on Facebook Share on Linkedin
David Bennett
The 57-year-old patient was able to communicate with his family in his final hours. 
READ MORE >

DOACs an effective substitute for VKAs after AFib patients undergo bioprosthetic valve replacement

Direct oral anticoagulants are noninferior to vitamin K antagonists when treating this important patient population, researchers reported. 

READ MORE >
durbin-ama-opioid. The American College of Cardiology (ACC) and American Heart Association (AHA) have published new guidelines focused on the diagnosis, treatment and management of patients with chronic coronary disease (CCD).
Share on Twitter Share on Facebook Share on Linkedin

DOACs an effective substitute for VKAs after AFib patients undergo bioprosthetic valve replacement

Share on Twitter Share on Facebook Share on Linkedin
durbin-ama-opioid. The American College of Cardiology (ACC) and American Heart Association (AHA) have published new guidelines focused on the diagnosis, treatment and management of patients with chronic coronary disease (CCD).
Direct oral anticoagulants are noninferior to vitamin K antagonists when treating this important patient population, researchers reported. 
READ MORE >

In Other News

VIDEO: Should women wait to get mammograms after COVID vaccination?

In an exclusive video, Stacey Wolfson, MD, and Beatriu Reig, MD, MPH, from the NYU Grossman School of Medicine, discuss the findings of their new analysis. 

READ MORE >
Stacey Wolfson, MD, chief resident, and Beatriu Reig, MD, MPH, clinical assistant professor of radiology, Department of Radiology, NYU Grossman School of Medicine, explain the findings of a study they were the lead authors on published in Radiology. Their study looked at 1,200 women who were vaccinated and received breast imaging exams, and they found several cancers, so their conclusion is not to wait for breast imaging after receiving a COVID vaccine or booster.
Share on Twitter Share on Facebook Share on Linkedin

VIDEO: Should women wait to get mammograms after COVID vaccination?

Share on Twitter Share on Facebook Share on Linkedin
Stacey Wolfson, MD, chief resident, and Beatriu Reig, MD, MPH, clinical assistant professor of radiology, Department of Radiology, NYU Grossman School of Medicine, explain the findings of a study they were the lead authors on published in Radiology. Their study looked at 1,200 women who were vaccinated and received breast imaging exams, and they found several cancers, so their conclusion is not to wait for breast imaging after receiving a COVID vaccine or booster.
In an exclusive video, Stacey Wolfson, MD, and Beatriu Reig, MD, MPH, from the NYU Grossman School of Medicine, discuss the findings of their new analysis. 
READ MORE >

AI tool achieves excellent agreement for knee OA severity classification

Many decision support tools catered to knee osteoarthritis have emerged in recent years, but external validation that ensures these algorithms can operate in a clinical setting has been lacking.

READ MORE >
Share on Twitter Share on Facebook Share on Linkedin

AI tool achieves excellent agreement for knee OA severity classification

Share on Twitter Share on Facebook Share on Linkedin
Many decision support tools catered to knee osteoarthritis have emerged in recent years, but external validation that ensures these algorithms can operate in a clinical setting has been lacking.
READ MORE >

Innovate Healthcare thanks our partners for supporting our newsletters.
Sponsorship has no influence on editorial content.

Interested in reaching our audiences, contact our team

*|LIST:ADDRESSLINE|*

You received this email because you signed up for newsletters from Innovate Healthcare.
Change your preferences or unsubscribe here

Contact Us  |  Unsubscribe from all  |  Privacy Policy

© Innovate Healthcare, a TriMed Media brand
Innovate Healthcare

Recent Newsletters

Medtech giant makes big move | The world’s top hospitals for heart surgery | New CPT codes | PET vs. SPECT | TAVR tech recalled
AI is gaining ground, but clinicians run the show | Siemens Healthineers doubles down | Electrophysiologist compensation
News Alert: FDA shares warning about heart valve tech after patient death
Cardiologist pay & productivity are up | FDA clears PE thrombectomy devices | Cardiology tech in spotlight | Gore's new approval
Cardiology salaries on the rise | The climbing costs of care | M&A trends | Siemens Healthineers, J&J make big business moves
Major MRI trends | Blood thinner recalled | When to perform PCI before TAVR | How to build a CCTA program | Steroids & the heart
CMS boosts coverage for heart failure tech | FDA approves CardioMEMS updates | LVADs linked to strokes, other risks
Newsletter archive
  • Home
  • News
  • Article Archive
  • Custom Content
  • Webinars
  • Press Releases
  • Content Studio
  • Advertising
  • Submit Press Release
  • Contact Us
  • Terms of Use
  • Privacy Policy
  • Cardiovascular Business
  • HealthExec
  • Radiology Business
  • Press Releases
  • Submit Press Release
© 2026 Innovate Healthcare | All Rights Reserved. | Terms of Use | Privacy Policy
Design by Adaptive Theme